Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Microbiology

An Observational Laboratory-Based Assessment of SARS-CoV-2 Molecular Diagnostics in Benin, Western Africa

Anna-Lena Sander et al.

Summary: Limited by insufficient diagnostic capacity, the spread of SARS-CoV-2 in Africa has been challenging. An increase in COVID-19-related diagnostic workload in the central laboratory of Benin, Western Africa, was observed, with genomic surveillance showing diverse SARS-CoV-2 lineages introduced by travelers. The validated diagnostic kit exhibited high sensitivity and specificity, highlighting the burden on national reference laboratories in resource-limited settings.

MSPHERE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

V. Shinde et al.

Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Chang Liu et al.

Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.

CELL (2021)

Add to Collection

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Alejandro Jara et al.

Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Pinja Jalkanen et al.

Summary: The study shows that the second dose of the BNT162b2 vaccine can induce cross-neutralization to some extent of SARS-CoV-2 variants, providing partial protection. Despite the reduced neutralization effect on the B.1.351 variant, the majority of vaccinees still have some level of protection.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences